Health Care [ 5/12 ] | Pharmaceuticals [ 23/74 ]
NYSE | Common Stock
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands.
It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio.
The company operates in Japan, the United States.
Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa.
The company was founded in 1781 and is headquartered in Chuo, Japan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 30, 26 | 0.48 Increased by +310.90% | 0.41 Increased by +17.07% |
| Jan 29, 26 | 0.21 Increased by +339.12% | - |
| Oct 30, 25 | -0.03 Decreased by -100.09% | 0.15 Decreased by -116.75% |
| Jul 30, 25 | 151.00 Increased by +78.42 K% | 0.20 Increased by +75.17 K% |
| May 8, 25 | -0.23 Decreased by -3.40 K% | -0.17 Decreased by -37.11% |
| Jan 30, 25 | 0.05 Decreased by -99.86% | 0.63 Decreased by -92.41% |
| Oct 31, 24 | 29.07 Increased by +287.55% | 87.45 Decreased by -66.76% |
| Jul 31, 24 | 0.19 Decreased by -99.33% | 0.12 Increased by +56.60% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 1.11 T Increased by +5.81% | -24.77 B Increased by +76.00% | Decreased by -2.22% Increased by +77.32% |
| Dec 31, 25 | 1.21 T Increased by +6.04% | 105.51 B Increased by +343.52% | Increased by +8.70% Increased by +318.27% |
| Sep 30, 25 | 1.11 T Decreased by -5.38% | -11.80 B Decreased by -112.82% | Decreased by -1.06% Decreased by -113.55% |
| Jun 30, 25 | 1.11 T Decreased by -8.39% | 124.24 B Increased by +30.44% | Increased by +11.23% Increased by +42.38% |
| Mar 31, 25 | 1.05 T Increased by +0.24% | -103.20 B Decreased by -3.32 K% | Decreased by -9.80% Decreased by -3.31 K% |
| Dec 31, 24 | 1.14 T Increased by +2.96% | 23.79 B Decreased by -77.50% | Increased by +2.08% Decreased by -78.15% |
| Sep 30, 24 | 1.18 T Increased by +12.75% | 92.05 B Increased by +291.64% | Increased by +7.83% Increased by +269.98% |
| Jun 30, 24 | 1.21 T Increased by +14.11% | 95.25 B Increased by +6.55% | Increased by +7.88% Decreased by -6.63% |